5-Methyl-5(H)-cyclopentapyrazine
Common Name: |
5-Methyl-5(H)-cyclopentapyrazine |
IUPAC Name: |
5-methyl-5H-cyclopenta[b]pyrazine |
Molecular Formula: |
C10H14O |
SMILES: |
CC1C=CC2=NC=CN=C12 |
Inchi: |
1S/C8H8N2/c1-6-2-3-7-8(6)10-5-4-9-7/h2-6H,1H3 |
Inchi Key: |
WWUFRIQCZCLXPV-UHFFFAOYSA-N |
Cas No: |
65128-99-6 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
1 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
2 |
Name |
Value |
Molecular Weight (g/mol) |
150.22 |
Mass (g/mol) |
132.069 |
Molar Refractivity |
47.06 |
Net Charge |
|
HBD |
|
HBA |
1 |
Rt Bonds |
0 |
Rings |
2 |
TPSA |
17.07 |
Hetero Atoms |
2 |
Heavy Atoms |
11 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
249.5 |
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.50 |
LogP |
1.607 |
iLOGP |
2.39 |
XLOGP3 |
2.72 |
WLOGP |
2.49 |
MLOGP |
2.10 |
ESOL Log S |
-2.48 |
ESOL Solubility (mg/ml) |
0.492 |
ESOL Solubility (mol/l) |
0.003 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-2.73 |
Ali Solubility (mg/ml) |
0.28 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-2.46 |
Silicos-IT Solubility (mg/ml) |
0.52 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-5.29 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.597 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.199 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
1 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |